Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Antibody–drug conjugates (ADC) are a rapidly growing class of targeted cancer treatments, but the field has experienced significant challenges from their complex design. This study examined the multiscale distribution of sacituzumab govitecan (SG; Trodelvy), a recently clinically approved ADC, to cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopp, Anna, Hofsess, Scott, Cardillo, Thomas M., Govindan, Serengulam V., Donnell, Jennifer, Thurber, Greg M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812893/
https://www.ncbi.nlm.nih.gov/pubmed/36190986
http://dx.doi.org/10.1158/1535-7163.MCT-22-0375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812893/
https://www.ncbi.nlm.nih.gov/pubmed/36190986
http://dx.doi.org/10.1158/1535-7163.MCT-22-0375

Ejemplares similares